Pain for AcelRx as $40 million IPO dulls ambitions
14 February 2011
Nancy Faigen
Please Login to read the full article.
14 February 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Cadence Pharma raises $71.3M in offering, to support Ofirmev launch
- Cara taps Korean firm as first licensee for its lead analgesic
- Alkermes' PhII ALKS-5461: new mechanism, opiate receptor modulation, for refractory depression
- Pacira Pharma in $45.5M follow-on to commercialise approved pain product
COMMENT
Other Informa Comment
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
